Psychedelics.,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 7
Published: April 22, 2025
Psychedelic
compounds
have
demonstrated
remarkable
therapeutic
potential
for
treating
neuropsychiatric
disorders
by
promoting
sustained
neuroplasticity
in
the
prefrontal
cortex
(PFC).
Cognitive
flexibility—the
ability
to
adapt
previously
learned
rules
novel
situations—represents
a
critical
PFC
function
that
is
frequently
impaired
depression,
PTSD,
and
neurodegenerative
conditions.
In
this
study,
we
demonstrate
single
administration
of
selective
serotonin
2A
receptor
agonist
25CN-NBOH
produces
significant,
long-lasting
improvements
cognitive
flexibility
both
male
female
mice
when
measured
2–3
weeks
posttreatment.
Using
automated
sequential
learning
paradigm,
psychedelic-treated
showed
superior
adaptability
rule
reversal
tasks
compared
saline
controls,
as
evidenced
enhanced
poke
efficiency,
higher
percentages
correct
trials,
increased
reward
acquisition.
These
behavioral
findings
complement
existing
cellular
research
showing
psychedelic-induced
structural
remodeling
uniquely
benefits
persisting
after
psychedelic
dose.
Our
task
provides
high-throughput
method
evaluating
effects
various
compounds,
offering
important
implications
applications
conditions
characterized
rigidity,
including
potentially
Alzheimer's
disease.
Journal of Neuroscience,
Journal Year:
2023,
Volume and Issue:
43(45), P. 7472 - 7482
Published: Nov. 8, 2023
Serotonergic
psychedelics,
such
as
psilocybin
and
LSD,
have
garnered
significant
attention
in
recent
years
for
their
potential
therapeutic
effects
unique
mechanisms
of
action.
These
compounds
exert
primary
through
activating
serotonin
5-HT
Biological Psychiatry Cognitive Neuroscience and Neuroimaging,
Journal Year:
2024,
Volume and Issue:
9(5), P. 490 - 499
Published: Feb. 9, 2024
There
has
been
renewed
interest
in
the
use
of
3,4-methylenedioxy-methamphetamine
(MDMA)
and
serotonergic
psychedelics
treatment
multiple
psychiatric
disorders.
Many
these
compounds
are
known
to
produce
prosocial
effects,
but
how
effects
relate
therapeutic
efficacy
extent
which
unique
a
particular
drug
class
is
unknown.
In
this
article,
we
present
narrative
overview
compare
evidence
for
MDMA
elucidate
shared
mechanisms
that
may
underlie
process.
We
discuss
4
categories
effects:
altered
self-image,
responses
social
reward,
negative
input,
neuroplasticity.
While
both
drugs
alter
self-perception,
do
so
way
less
related
experience
mystical-type
states
than
psychedelics.
case
supports
ability
enhance
suggests
also
so,
more
research
needed
area.
Both
classes
consistently
dampen
reactivity
stimuli.
Finally,
preclinical
induce
neuroplasticity,
promoting
adaptive
rewiring
neural
circuits,
be
helpful
trauma
processing.
they
differ
through
this.
These
differences
affect
types
psychosocial
interventions
work
best
with
each
compound.
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Journal Year:
2024,
Volume and Issue:
134, P. 111058 - 111058
Published: June 15, 2024
Mounting
evidence
points
towards
a
crucial
role
of
the
kynurenine
pathway
(KP)
in
altered
gut-brain
axis
(GBA)
balance
severe
mental
illness
(SMI,
namely
depression,
bipolar
disorder,
and
schizophrenia)
cardiometabolic
comorbidities.
Preliminary
shows
that
serotonergic
psychedelics
their
analogues
may
hold
therapeutic
potential
addressing
KP
dysregulated
GBA
SMI
In
fact,
aside
from
effects
on
mood,
elicit
improvement
preclinical
models
obesity,
metabolic
syndrome,
vascular
inflammation,
which
are
highly
comorbid
with
SMI.
Here,
we
review
literature
modulation
comorbidities,
application
to
address
brain
systemic
dysfunction
underlying
Psychedelics
might
therapeutically
modulate
comorbidities
either
directly,
via
altering
by
influencing
rate-limiting
enzymes
affecting
levels
available
tryptophan,
or
indirectly,
gut
microbiome,
metabolome,
metabolism,
immune
system.
Despite
promising
preliminary
evidence,
mechanisms
outcomes
remain
largely
unknown
require
further
investigation.
Several
concerns
discussed
surrounding
side
this
approach
specific
cohorts
individuals
Psychopharmacology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: May 14, 2024
Abstract
Recent
research
with
classic
psychedelics
suggests
significant
therapeutic
potential,
particularly
for
neuropsychiatric
disorders.
A
mediating
influence
behind
symptom
resolution
is
thought
to
be
the
personal
insight
–
at
times,
bordering
on
mystical
one
acquires
during
acute
phase
of
a
psychedelic
session.
Indeed,
current
clinical
trials
have
found
strong
correlations
between
subjective
effects
(ASE)
under
and
their
enduring
properties.
However,
potential
barriers
widespread
implementation,
including
healthcare
resource-intensive
nature
sessions
exclusion
certain
at-risk
patient
groups,
there
an
active
search
determine
whether
ASE
elimination
can
accompanied
by
retention
persisting
benefits
these
class
compounds.
Recognizing
aberrant
underlying
neural
circuitry
that
characterizes
range
disorders,
promote
neuroplastic
changes
may
correct
abnormal
circuitry,
investigators
are
rushing
design
discover
compounds
psychoplastogenic,
but
not
hallucinogenic
(i.e.,
ASE),
potential.
These
efforts
paved
discovery
‘non-psychedelic/subjective
psychedelics’,
or
lack
activity
efficacy
in
preclinical
models.
This
review
aims
distill
evidence
both
surrounding
question:
dissociated
from
sustained
properties?
Several
plausible
scenarios
then
proposed
offer
clarity
potentially
answer
this
question.
British Journal of Pharmacology,
Journal Year:
2024,
Volume and Issue:
181(19), P. 3627 - 3641
Published: June 2, 2024
Demand
for
new
antidepressants
has
resulted
in
a
re-evaluation
of
the
therapeutic
potential
psychedelic
drugs.
Several
tryptamines
found
psilocybin-containing
"magic"
mushrooms
share
chemical
similarities
with
psilocybin.
Early
work
suggests
they
may
biological
targets.
However,
few
studies
have
explored
their
pharmacological
and
behavioural
effects.
